Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 25 mg - capsule - excipient ingredients: magnesium stearate; gelatin; croscarmellose sodium; mannitol; povidone; microcrystalline cellulose; iron oxide red; titanium dioxide; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 25 mg - capsule - excipient ingredients: gelatin; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; povidone; mannitol; titanium dioxide; iron oxide red; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 37.5 mg - capsule - excipient ingredients: povidone; gelatin; microcrystalline cellulose; magnesium stearate; mannitol; titanium dioxide; croscarmellose sodium; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 50 mg - capsule - excipient ingredients: gelatin; titanium dioxide; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; iron oxide red; povidone; mannitol; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 12.5 mg - capsule - excipient ingredients: magnesium stearate; mannitol; gelatin; iron oxide red; microcrystalline cellulose; povidone; croscarmellose sodium; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sunitinib malate, quantity: 66.825 mg (equivalent: sunitinib, qty mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide black; iron oxide yellow; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - arx-sunitinib is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sunitinib malate, quantity: 50.119 mg (equivalent: sunitinib, qty mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - arx-sunitinib is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sunitinib malate, quantity: 33.413 mg (equivalent: sunitinib, qty 25 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - arx-sunitinib is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sunitinib malate, quantity: 16.706 mg (equivalent: sunitinib, qty 12.5 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - arx-sunitinib is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - sunitinib malate, quantity: 50.118 mg (equivalent: sunitinib, qty 37.5 mg) - capsule, hard - excipient ingredients: croscarmellose sodium; mannitol; gelatin; pregelatinised maize starch; titanium dioxide; magnesium stearate; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - sunitinib msn is indicated for;,treatment of advanced renal cell carcinoma (rcc),treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net)